Prophylaxis and High-Risk Groups
Palivizumab is a monoclonal antibody recommended by the American Academy of Pediatrics (AAP) to be administered to high risk infants and young children likely to benefit from immunoprophylaxis based on gestational age, certain underlying medical conditions, and RSV seasonality. It is given in monthly intramuscular injections during the RSV season, which generally occurs during fall, winter and spring in most locations in the United States.
On July 28, 2014, AAP released updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for RSV infection. For specific and latest palivizumab guidance, please consult the AAP policy statement. An accompanying AAP technical report provides additional context and rationale for the guidance.
CDC provides recommendations for preventing healthcare-associated pneumonia, including RSV. State health departments and institutions may have their own individual guidance as well. See the Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee for more information.
- Page last reviewed: November 4, 2014
- Page last updated: December 4, 2014
- Content source: